<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01508858</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1330</org_study_id>
    <secondary_id>2006-003904-21</secondary_id>
    <nct_id>NCT01508858</nct_id>
  </id_info>
  <brief_title>Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women</brief_title>
  <official_title>A Double-blind, Two Period Cross-over, Single Centre Trial in Healthy Subjects Investigating the Influence on the Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Drug After Multiple Dose Administration of Liraglutide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate if liraglutide
      changes AUC (area under the curve) of ethinylestradiol and levonorgestrel administered as a
      combination contraceptive drug (Neovletta®).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of ethinylestradiol</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of levonorgestrel</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (0-t)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, maximum concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to reach Cmax</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½, terminal half-life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment period 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levonorgestrel / ethinylestradiol</intervention_name>
    <description>One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal woman

          -  Body Mass Index (BMI) between 18.0-30.0 kg/m^2 (both inclusive)

          -  Good general health as judged by the investigator, based on medical history, physical
             examination including 12-lead ECG (electrocardiogram), vital signs, blood and urinary
             laboratory assessments

        Exclusion Criteria:

          -  History of any clinically significant renal, hepatic, cardiovascular, pulmonary,
             gastrointestinal, metabolic, endocrine, haematological, neurological, psychiatric
             disease or other major disorders that may interfere with the objectives of the trial,
             as judged by the investigator

          -  Impaired renal function

          -  Active hepatitis B and/or active hepatitis C

          -  Positive HIV (human immunodeficiency virus) antibodies

          -  Known or suspected allergy to trial products or related products

          -  Pregnant or positive pregnancy test at screening or nursing mother

          -  Use of prescription or non-prescription medication within 2 weeks prior to first
             dosing with trial products which in the Investigators opinion will interfere with the
             pharmacokinetics of the compounds in Neovletta®

          -  Use of hormone replacement therapy within 4 weeks prior to starting dosing with trial
             product

          -  History of alcoholism or drug abuse

          -  Smoking of more than 10 cigarettes per day, or the equivalent for other tobacco
             products

          -  Habitual excessive consumption of methylxanthine-containing beverages and foods
             (coffee, tea, soft drinks such as cola, chocolate) as judged by the Investigator

          -  Excessive consumption of a diet deviating from a normal diet as judged by the
             Investigator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>75323</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12. Review. Erratum in: Diabetes Care. 2015 Aug;38(8):1622.</citation>
    <PMID>25504028</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>January 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2012</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

